Digital Guide: PARP Inhibitors for Ovarian Cancer - Salt Lake City

Dr. Derrick Haslem's guide to treating ovarian cancer with PARP inhibitors

×

This is Dr. Derrick Haslem’s guide to treating ovarian cancer with PARP inhibitors.

Dr. Haslem, of Intermountain Healthcare, has collaborated with SurvivorNet for this resource. People in the ovarian cancer community tell us that hearing advice like this, and knowing the options, has helped them make better decisions and reduce anxiety.

Dr. Derrick Haslem Intermountain Healthcare

Your Digital Guide begins below: 2 Chapters / 2 Video Segments

Need to Know: PARP Inhibitors (1)
1. What Does a New Ovarian Cancer Drug Combo Approval Mean for Patients?

Dr. Derrick Haslem

A new drug combination may help more women with ovarian cancer, and extend the time before the cancer recurs.

New Approvals (1)
2. Most Recent PARP Inhibitor Approval for Ovarian Cancer

Dr. Derrick Haslem

PARP inhibitors target ovarian cancer in a different way than traditional treatments like chemotherapy. One PARP inhibitor called niraparib (Zejula) is showing particularly promising results.

×

Get SurvivorNet in Your Inbox

Our newsletter – vital information, hope, and healing, delivered weekly.

Never want to see this again? Click here to dismiss this module permanently.
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.